ADVANTAGE OF LIVE ATTENUATED COLD-ADAPTED INFLUENZA A VIRUS OVER INACTIVATED VACCINE FOR A/WASHINGTON/80 (H3N2) WILD-TYPE VIRUS INFECTION
- 31 March 1984
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 323 (8379), 705-708
- https://doi.org/10.1016/s0140-6736(84)92222-0
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Dose Response of Influenza A/Washington/897/80 (H3N2) Cold-Adapted Reassortant Virus in Adult VolunteersThe Journal of Infectious Diseases, 1984
- Evaluation of a Cold-Recombinant Influenza Virus Vaccine in FerretsThe Journal of Infectious Diseases, 1982
- Cold-Adapted Recombinant Influenza A Virus Vaccines in Seronegative Young ChildrenThe Journal of Infectious Diseases, 1982
- Characterization and clinical evaluation of live influenza a vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strainsAntiviral Research, 1981
- Temperature-sensitive mutants of influenza A virus: Evaluation of the Alaska/77-ts-1 A 2 temperature-sensitive recombinant virus in seronegative adult volunteersArchiv für die gesamte Virusforschung, 1980
- Studies in man with cold‐recombinant influenza virus (h1n1) live vaccinesJournal of Medical Virology, 1980
- Pilot Studies on Recombinant Cold-Adapted Live Type A and B Influenza Virus VaccinesThe Journal of Infectious Diseases, 1977
- From the National Institutes of HealthThe Journal of Infectious Diseases, 1973
- Temperature-Sensitive Mutants of Influenza Virus. II. Attenuation of ts Recombinants for ManThe Journal of Infectious Diseases, 1972
- Correlated Studies of a Recombinant Influenza-Virus Vaccine. III. Protection against Experimental Influenza in ManThe Journal of Infectious Diseases, 1971